Orgenesis Inc. (ORGS)’s Financial Results Comparing With Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA)

Both Orgenesis Inc. (NASDAQ:ORGS) and Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) are Biotechnology companies, competing one another. We will compare their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orgenesis Inc. 18.66M 4.19 19.18M -1.40 0.00
Sienna Biopharmaceuticals Inc. N/A 0.00 73.47M -2.77 0.00

Table 1 highlights Orgenesis Inc. and Sienna Biopharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Orgenesis Inc. -102.79% -70.9% -31.2%
Sienna Biopharmaceuticals Inc. 0.00% -97.5% -50.2%


Orgenesis Inc.’s Current Ratio and Quick Ratio are 1.8 and 1.7 respectively. The Current Ratio and Quick Ratio of its competitor Sienna Biopharmaceuticals Inc. are 4.9 and 4.9 respectively. Sienna Biopharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Orgenesis Inc.

Insider & Institutional Ownership

Roughly 2.8% of Orgenesis Inc. shares are held by institutional investors while 32.3% of Sienna Biopharmaceuticals Inc. are owned by institutional investors. 26.45% are Orgenesis Inc.’s share held by insiders. Competitively, Sienna Biopharmaceuticals Inc. has 4.3% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Orgenesis Inc. -0.77% 19.44% -9.63% -18.23% -35.5% 10.26%
Sienna Biopharmaceuticals Inc. 13.44% 7.09% -71.81% -83.09% -82.01% 23.71%

For the past year Orgenesis Inc.’s stock price has smaller growth than Sienna Biopharmaceuticals Inc.


On 6 of the 9 factors Orgenesis Inc. beats Sienna Biopharmaceuticals Inc.

Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. The company's Contract Development and Manufacturing Organization segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and GMP contract manufacturing services. Its Cellular Therapy Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin-producing cells for patients with diabetes. Orgenesis Inc. has a collaboration agreement with Biosequel LLC to carry out clinical trials and market its products in Russia, Belarus, and Kazakhstan. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The companyÂ’s lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.